Targeted therapeutic platform WaveBreak focuses on transient protein intermediates and oligomers in neurodegenerative pathways, presenting a differentiated angle for partnerships or licensing deals with pharma companies seeking novel mechanisms beyond conventional discovery.

Clinical unmet needs The initial focus on Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS aligns with large, persistent market demand and potential co-development opportunities with biopharma players looking to diversify their neurodegenerative portfolios.

Early-stage scale With revenue in the low millions and a recent funding of forty million, WaveBreak is positioned for partnerships that can provide additional capital and access to larger development programs without requiring immediate large-scale commercialization.

Agile team advantage A small team footprint (2-10 employees) can enable rapid decision-making and flexible collaboration models with external CROs, academic labs, or biotech peers for joint discovery campaigns and milestone-driven collaborations.

Tech-enabled outreach The company’s tech stack and digital presence (analytics, SEO, and collaboration tools) offers multiple channels to identify and engage target decision-makers in pharma, enabling precision outreach and measurable engagement with potential partners.